🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Addition of a Pectoserratus Block to Interscalene Block in Patients Undergoing Total Shoulder Replacement

RecruitingPhase 4Ages 18 Years - 85 YearsAllUniversity of Minnesota
NCT06143306 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The use of ISB in patients undergoing total shoulder arthroplasty (TSA) is the gold standard and results in significantly reduced pain scores and opioid use. However, patients still have pain and the majority require opioids postoperatively as the interscalene block (ISB) doesn't cover all of the dermatomes impacted during TSA. A pectoserratus block typically provides coverage to additional dermatomes that are impacted during TSA. Currently ISB is performed for every patient and perform a pectoserratus block to a portion of our patients undergoing TSA. The purpose of the study is to determine if the addition of the pectoserratus block to the ISB will results in improvement in pain control and decrease in opioid use, among patients undergoing TSA. This is a randomized prospective controlled trial. All patients undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty a

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty; * Patients aged 18-85 years old. Exclusion Criteria: * Patients who have an exclusion to regional anesthesia such as pre-existing nerve damage to their brachial plexus or infection at the site of injection. * Patients who have exclusion to interscalene blockade such as severe lung disease. * Non-English speakers will be excluded because pain scales are not validated in other languages and there is lack of standardization of pain reporting. * Pregnant patients * Patients who are currently using opioids and patients with a diagnosis of chronic pain will be excluded.
💊

What it tests

  • bupivacaine.
  • Saline
📍

Where

1 site
University of Minnesota
Minneapolis, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy